
New Treatment for IDH mt Gliomas
Dr. Kathryn Nevel talks with Dr. Ingo Mellinghoff about how vorasidenib improved progression-free survival in patients with Isocitrate dehydrogenase (IDH)–mutant grade 2 gliomas.
Read the related article in The New England Journal of Medicine.
Visit NPUb.org/Podcast for associated article links.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.